AG

Abhijit Gunderao Patil

Active Director Director DIN 11476460
DIN 11476460 First appointment Jan 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Abhijit Gunderao Patil

Data last updated:

Abhijit Gunderao Patil is a Director at Sunfinity Life Science Private Limited (since 2026).

DIN 11476460
Primary Designation Director
First Appointment 10 Jan 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Jan 2026Active

Directorship timeline

Open interactive timeline →
Sunfinity Life Science Private Limited
Premium access

Shareholding and investment profile for Abhijit Gunderao Patil

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abhijit Gunderao Patil

Abhijit Gunderao Patil currently holds 1 directorship: Sunfinity Life Science Private Limited (Director, since 10 Jan 2026).

Abhijit Gunderao Patil was first appointed on 10 Jan 2026 as Director at Sunfinity Life Science Private Limited.

The current boards of Abhijit Gunderao Patil's companies include Amit Govind Narvekar (Sunfinity Life Science Private Limited), Kiran Panditrao Patil (Sunfinity Life Science Private Limited), Nilesh Krishanat Mane (Sunfinity Life Science Private Limited), Nilesh Pandurang Patil (Sunfinity Life Science Private Limited), Raisa Suhel Shaikh (Sunfinity Life Science Private Limited), Sarika Vikas Patil (Sunfinity Life Science Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available